"The acquisition enables DNAPrint to establish a base of operations in the San Francisco Bay biotech corridor and broadens our sales and marketing opportunities on the West Coast," stated President and Chief Executive Officer Richard Gabriel. "By centralizing our consumer genomics and law enforcement forensics production work at Trace's state-of-the art custom laboratory in San Francisco, we can concentrate on the acceleration of research and development at our Sarasota headquarters."

Trace ( http://www.tracegenetics.com ) brings two new complementary technologies to DNAPrint's autosomal testing for determining the percentage of a person's ancestry -- y-chromosome testing for tracing ancestry by following the paternal line and mitochondrial (mtDNA) x-chromosome testing for the maternal line. Trace also maintains a Native American DNA databank which, when combined with DNAPrint's, will be one of the largest in North America. In addition, Trace maintains expertise in ancient DNA analysis from mummified and fossilized remains. DNAPrint's proprietary human genome technology is focused on three areas: pharmacogenomics, forensics, and genealogy. All three are based on core technology for targeting single nucleotide polymorphisms (SNPs), which enables the Company to provide novel predictive genetic tests at a significant cost advantage.

Mr. Gabriel noted that Trace's co-founders, Ripan S. Malhi, Ph.D., and Jason Eshelman, Ph.D., will join the staff of DNAPrint genomics. "We are pleased that these two talented scientists are becoming part of the DNAPrint family," Mr. Gabriel stated. "Their expertise will bring an invaluable asset to the Company at a time when we are entering a period of expansion and growth."

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. ( http://www.dnaprint.com ) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT- 401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre- clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response.

Forward-Looking Statements

All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

     Company Contact:
     Richard Gabriel
     President and CEO
     941-366-3400
          -or-
     Ron Stabiner
     The Wall Street Group, Inc.
     212-888-4848